Brief: Nabriva Therapeutics Announces First Patient Enrolled In Phase 1 Trial Of Xenleta In Adult Patients With Cystic Fibrosis
11/04/2022 21:31
April 11 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN
PHASE 1
TRIAL OF XENLETA® (LEFAMULIN) IN ADULT PATIENTS WITH CYSTIC
FIBROSIS
Source text for Eikon: ID:nGNX2d4Z0M
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update